No Data
No Data
CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress
CytomX Therapeutics Welcomes New Director and Updates Bylaws
Press Release: CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of condi
CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration With Astellas
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
CytomX Therapeutics Braces for Increased Compliance Costs as It Outgrows 'Smaller Company' Status
No Data